UC Davis Comparative Oncology Training Program
UC Davis Comparative Oncology Training Program
批准号:
10686927
负责人:
Robert J. Canter
金额:
$29.05万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-01 至 2025-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Preclinical animal models have been the foundation for the development of novel cancer therapies. Historically,
this foundation has relied on mouse models. While mouse models are fundamentally important, the models are
insufficient and need to be complemented. Companion animals are an important combination of outbred
animals that have spontaneous cancer development with an intact immune system and have environmental
and epigenetic exposures as humans. Tackling complex cancer research problems should include
investigators with broad experience across animal and human species presenting a unique opportunity for
DVMs and MDs to have a crucial role in basic to translational research. Veterinarians can strengthen
comparative approaches essential to multidisciplinary research accelerating innovative treatments for animals
and humans. Medical doctors bring a patient-centered approach linking biology with clinical therapy.
Unfortunately, recruiting and retaining biomedical scientists with comparative oncology expertise, especially
DVM or MD clinician-scientists, continues to be a challenging issue facing the broader research community.
The Comparative Oncology Training Program (T32) will provide an outstanding environment to train
predoctoral (DVM/PhD) students and post-DVM or post-MD fellows who are interested in cancer research. To
accomplish this goal, Drs. Chen, Kent, and Canter (MPIs) organized a diverse team of twenty-seven UC Davis
faculty mentors from the School of Veterinary Medicine, School of Medicine, College of Biological Science,
College of Agricultural and Environmental Sciences, and College of Engineering. The faculty mentors are
accomplished biomedical investigators with NCI or cancer-related funding. The proposed program will leverage
the NCI-designated UC Davis Comprehensive Cancer Center and will be fully integrated into the Center’s
cancer education program. The T32 program’s objectives are to: 1) recruit and retain a diverse group of
clinician-scientists that prepares them to become future leaders in academia, government service and public
health, 2) expose the T32 scholars to cancer-focused career paths, and 3) train the scholars to use
comparative medicine to address human cancer biology. The objectives will be accomplished by providing up
to 3-year funding support for DVM/PhD dual-degree predoctoral students and post-DVM or post-MD
postdoctoral fellows. During the training, the T32 scholars will enhance their knowledge through tailored
coursework, mentored research, multidisciplinary interactions, and career development activities. By the end
of the grant period, we expect to train eleven professionals encompassing two dual-degree DVM/PhD
students, seven post-DVM fellows, and two post-MD fellows to become highly-qualified basic and translational
comparative oncology researchers.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.jamcollsurg.2021.02.014
发表时间:
2021-07
期刊:
Journal of the American College of Surgeons
影响因子:
5.2
作者:
[Perry LM, Bateni SB, Bold RJ, Hoch JS]
通讯作者:
Hoch JS
DOI:
10.3390/jdb10010011
发表时间:
2022-02-08
期刊:
Journal of developmental biology
影响因子:
2.7
作者:
[Lee SY, Loll EG, Hassan AS, Cheng M, Wang A, Farmer DL]
通讯作者:
Farmer DL
DOI:
10.1245/s10434-020-09357-x
发表时间:
2021-05
期刊:
Annals of surgical oncology
影响因子:
3.7
作者:
[Perry LM, Bateni SB, Sauder CAM]
通讯作者:
Sauder CAM
Building a Culture of Support at a Pediatric Surgery Center Through Multidisciplinary Peer Support.
通过多学科同伴支持在小儿外科中心建立支持文化。
DOI:
10.1016/j.jss.2023.04.029
发表时间:
2023
期刊:
The Journal of surgical research
影响因子:
--
作者:
[Doyle,Kathleen, Murray,Trudee, Fong,IanC, Chavez,Angela, Rounds,Ginger, Linenberger,Michelle, Wieck,Minna]
通讯作者:
Wieck,Minna
DOI:
10.1638/2021-0082
发表时间:
2022-03
期刊:
JOURNAL OF ZOO AND WILDLIFE MEDICINE
影响因子:
0.7
作者:
[Alex, Charles E., Kubiski, Steven, V, Jackson, Kenneth A., Wack, Raymund F., Pesavento, Patricia A.]
通讯作者:
Pesavento, Patricia A.
共 6 条
Targeting Lung Tissue Resident NK Cells with Inhaled IL-15 and TIGIT Blockade in Osteosarcoma
-
批准号:10438449
-
项目类别:
-
资助金额:$7.53万
-
财政年份:2022
-
负责人:Robert J. Canter
-
依托单位:
Targeting Lung Tissue Resident NK Cells with Inhaled IL-15 and TIGIT Blockade in Osteosarcoma
-
批准号:10578729
-
项目类别:
-
资助金额:$7.57万
-
财政年份:2022
-
负责人:Robert J. Canter
-
依托单位:
Gene Expression Analysis of Dog Natural Killer Cells as Immunotherapy Target
-
批准号:10201901
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2021
-
负责人:Robert J. Canter
-
依托单位:
Gene Expression Analysis of Dog Natural Killer Cells as Immunotherapy Target
-
批准号:10372182
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2021
-
负责人:Robert J. Canter
-
依托单位:
UC Davis Comparative Oncology Training Program
-
批准号:10474468
-
项目类别:
-
资助金额:$42.91万
-
财政年份:2020
-
负责人:Robert J. Canter
-
依托单位:
UC Davis Comparative Oncology Training Program
-
批准号:10023113
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2020
-
负责人:Robert J. Canter
-
依托单位:
UC Davis Comparative Oncology Training Program
-
批准号:10248520
-
项目类别:
-
资助金额:$43.4万
-
财政年份:2020
-
负责人:Robert J. Canter
-
依托单位:
Gene Expression Analysis of Dog Natural Killer Cells Following Immunotherapy with Molecularly Targeted Radionuclide therapy or Inhaled IL-15
-
批准号:10287107
-
项目类别:
-
资助金额:$25.01万
-
财政年份:2017
-
负责人:Robert J. Canter
-
依托单位:
Enhancing natural killer immunotherapy with first-in-dog trials of inhaled recombinant IL-15 and super-agonist IL-15 in naturally occurring canine cancers
-
批准号:9449992
-
项目类别:
-
资助金额:$163.98万
-
财政年份:2017
-
负责人:Robert J. Canter
-
依托单位:
Enhancing natural killer immunotherapy with first-in-dog trials of inhaled recombinant IL-15 and super-agonist IL-15 in naturally occurring canine cancers
-
批准号:10260613
-
项目类别:
-
资助金额:$53.79万
-
财政年份:2017
-
负责人:Robert J. Canter
-
依托单位:
Enhancing natural killer immunotherapy with first-in-dog trials of inhaled recombinant IL-15 and super-agonist IL-15 in naturally occurring canine cancers
-
批准号:10247896
-
项目类别:
-
资助金额:$54.05万
-
财政年份:2017
-
负责人:Robert J. Canter
-
依托单位:
海外基金